Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - meningococcal polysaccharide group w135, quantity: 10 microgram; meningococcal polysaccharide group c, quantity: 10 microgram; meningococcal polysaccharide group a, quantity: 10 microgram; meningococcal polysaccharide group y, quantity: 10 microgram - injection, solution - excipient ingredients: sodium acetate; tetanus toxoid; sodium chloride; water for injections - menquadfi is indicated for active immunisation for the prevention of invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w and y.,the use of menquadfi should be in accordance with official recommendations.

Filipíny - angličtina - FDA (Food And Drug Administration)

broadchem philippines biopharma corporation; distributor: broadchem philippines biopharma corporation - inactivated pasteurella multocida , bordetella bronchiseptica toxoid vaccine (vet.) - emulsion for injection (im) - formulation: each dose (2 ml) contains: pasteurella multocida (115/a strain)................10^10 - 10^11 cfu pasteurella multocida (type d dermonecrotoxic toxoid)....... 2-4 ug bordetella bronchiseptica (strain 6230)........... .......... 10^10 - 10^11 cfu cfu - colony forming unit

Namibie - angličtina - Namibia Medicines Regulatory Council

serum institute of india ltd - adsorbed tetanus toxoid - injection - each single 0.5 ml human dose contains adsorbed tetanus toxoid ? 5 lf (? 40 iu)

Kanada - angličtina - Health Canada

sanofi pasteur limited - filamentous haemagglutinin; pertussis toxoid; pertactin; tetanus toxoid; fimbriae types 2 and 3 (fim); poliovirus type 1 mahoney (inactivated); poliovirus type 2 mef1 (inactivated); poliovirus type 3 saukett (inactivated); diphtheria toxoid - suspension - 5mcg; 2.5mcg; 3mcg; 5lf; 5mcg; 29unit; 7unit; 26unit; 2lf - filamentous haemagglutinin 5mcg; pertussis toxoid 2.5mcg; pertactin 3mcg; tetanus toxoid 5lf; fimbriae types 2 and 3 (fim) 5mcg; poliovirus type 1 mahoney (inactivated) 29unit; poliovirus type 2 mef1 (inactivated) 7unit; poliovirus type 3 saukett (inactivated) 26unit; diphtheria toxoid 2lf - vaccines

Kanada - angličtina - Health Canada

glaxosmithkline inc - diphtheria toxoid adsorbed; tetanus toxoid adsorbed; pertussis toxoid adsorbed; filamentous haemagglutinin adsorbed; pertactin adsorbed; inactivated poliovirus type i; inactivated poliovirus type ii; inactivated poliovirus type iii - suspension - 2.5lf; 5.0lf; 8mcg; 8mcg; 2.5mcg; 40d; 8d; 32d - diphtheria toxoid adsorbed 2.5lf; tetanus toxoid adsorbed 5.0lf; pertussis toxoid adsorbed 8mcg; filamentous haemagglutinin adsorbed 8mcg; pertactin adsorbed 2.5mcg; inactivated poliovirus type i 40d; inactivated poliovirus type ii 8d; inactivated poliovirus type iii 32d - vaccines

Kanada - angličtina - Health Canada

sanofi pasteur limited - diphtheria toxoid adsorbed; tetanus toxoid adsorbed - suspension - 2lf; 5lf - diphtheria toxoid adsorbed 2lf; tetanus toxoid adsorbed 5lf - toxoids

Kanada - angličtina - Health Canada

sanofi pasteur limited - pertactin; fimbriae; filamentous haemagglutinin; pertussis toxoid; tetanus protein; inactivated poliomyelitis vaccine (v.c.o.) type 3 saukett; inactivated poliomyelitis vaccine (v.c.o.) type 2 mef1; inactivated poliomyelitis vaccine (v.c.o.) type 1 mahoney; haemophilus influenzae type b-prp; tetanus toxoid; diphtheria toxoid - suspension - 3mcg; 5mcg; 20mcg; 20mcg; 30mcg; 26unit; 7unit; 29unit; 10mcg; 5lf; 15lf - pertactin 3mcg; fimbriae 5mcg; filamentous haemagglutinin 20mcg; pertussis toxoid 20mcg; tetanus protein 30mcg; inactivated poliomyelitis vaccine (v.c.o.) type 3 saukett 26unit; inactivated poliomyelitis vaccine (v.c.o.) type 2 mef1 7unit; inactivated poliomyelitis vaccine (v.c.o.) type 1 mahoney 29unit; haemophilus influenzae type b-prp 10mcg; tetanus toxoid 5lf; diphtheria toxoid 15lf

Kanada - angličtina - Health Canada

sanofi pasteur limited - pertactin; pertussis toxoid; diphtheria toxoid; tetanus toxoid; inactivated poliomyelitis vaccine (v.c.o.) type 1 mahoney; inactivated poliomyelitis vaccine (v.c.o.) type 2 mef1; inactivated poliomyelitis vaccine (v.c.o.) type 3 saukett; haemophilus influenzae type b-prp; tetanus protein; filamentous haemagglutinin; fimbriae - suspension - 3mcg; 20mcg; 15lf; 5lf; 29unit; 7unit; 26unit; 10mcg; 30mcg; 20mcg; 5mcg - pertactin 3mcg; pertussis toxoid 20mcg; diphtheria toxoid 15lf; tetanus toxoid 5lf; inactivated poliomyelitis vaccine (v.c.o.) type 1 mahoney 29unit; inactivated poliomyelitis vaccine (v.c.o.) type 2 mef1 7unit; inactivated poliomyelitis vaccine (v.c.o.) type 3 saukett 26unit; haemophilus influenzae type b-prp 10mcg; tetanus protein 30mcg; filamentous haemagglutinin 20mcg; fimbriae 5mcg - vaccines

Spojené státy - angličtina - NLM (National Library of Medicine)

msp vaccine company - corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (unii: irh51qn26h) (corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) - unii:irh51qn26h), clostridium tetani toxoid antigen (formaldehyde inactivated) (unii: k3w1n8yp13) (clostridium tetani toxoid antigen (formaldehyde inactivated) - unii:k3w1n8yp13), bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (unii: f4tn0ipy37) (bordetella pertussis toxoid antigen (glutaraldehyde inactivated) - unii:f4tn0ipy37 - vaxelis® is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis b, and invasive disease due to haemophilus influenzae (h. influenzae ) type b. vaxelis is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday). do not administer vaxelis to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to a previous dose of vaxelis, any ingredient of vaxelis, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis b vaccine, or h. influenzae type b vaccine [see description (11) .] do not administer vaxelis to anyone with a history of encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of a previous dose of a pertussis-containing vaccine, that is not attributable to another identifiable cause. do not administer vaxelis to anyone with a history of progressive neurologic disorder, inclu

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - poliovirus; pertactin; pertussis filamentous haemagglutinin; pertussis toxoid; diphtheria toxoid; hepatitis b surface antigen recombinant; tetanus toxoid -